Review
. 2013 Sep; 11(2):3-22.
doi: 10.1016/j.ejcsup.2013.07.029.

Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment

J Ribeiro 1 B Sousa 1 F Cardoso 1 
Affiliations
  • PMID: 26217109
  •     142 References
  •     2 citations

No abstract available

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
W Jonat, M Kaufmann, +14 authors, Zoladex Early Breast Cancer Research Association Study.
J Clin Oncol, 2002 Dec 19; 20(24). PMID: 12488406
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Ivana Sestak, Jack Cuzick, +5 authors, ATAC Trialists' Group.
Lancet Oncol, 2008 Aug 16; 9(9). PMID: 18703382
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.
Mitch Dowsett, Jack Cuzick, +16 authors, Richard Peto.
J Clin Oncol, 2009 Dec 02; 28(3). PMID: 19949017
Highly Cited.
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.
R W Stephens, N Brünner, F Jänicke, M Schmitt.
Breast Cancer Res Treat, 1999 Mar 05; 52(1-3). PMID: 10066075
Review.
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
Edith A Perez, Vera J Suman, +10 authors, Robert B Jenkins.
J Clin Oncol, 2011 Nov 02; 29(34). PMID: 22042958    Free PMC article.
Highly Cited.
The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.
Eva Thomas, Frankie A Holmes, +9 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2004 Jun 16; 22(12). PMID: 15197190
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Jack Cuzick, Ivana Sestak, +5 authors, ATAC/LATTE investigators.
Lancet Oncol, 2010 Nov 23; 11(12). PMID: 21087898
Highly Cited.
Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Eitan Amir, Bostjan Seruga, +2 authors, Alberto Ocaña.
J Natl Cancer Inst, 2011 Jul 12; 103(17). PMID: 21743022
Highly Cited. Systematic Review.
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Gong Tang, Steven Shak, +6 authors, Norman Wolmark.
Breast Cancer Res Treat, 2011 Jan 12; 127(1). PMID: 21221771    Free PMC article.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Martine J Piccart-Gebhart, Marion Procter, +30 authors, Herceptin Adjuvant (HERA) Trial Study Team.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236737
Highly Cited.
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni, Wolfgang Eiermann, +17 authors, Jose Baselga.
Lancet, 2010 Feb 02; 375(9712). PMID: 20113825
Highly Cited.
Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
F Boccardo, A Rubagotti, +10 authors, A Farris.
J Clin Oncol, 2000 Jul 15; 18(14). PMID: 10894871
Functional evaluation of plasmin formation in primary breast cancer.
P O Chappuis, B Dieterich, +4 authors, A P Sappino.
J Clin Oncol, 2001 May 16; 19(10). PMID: 11352966
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
Stella Mook, Marjanka K Schmidt, +10 authors, TRANSBIG Consortium.
Breast Cancer Res Treat, 2008 Jul 29; 116(2). PMID: 18661261
A Gompertzian model of human breast cancer growth.
L Norton.
Cancer Res, 1988 Dec 15; 48(24 Pt 1). PMID: 3191483
Highly Cited.
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.
Marieke E Straver, Annuska M Glas, +7 authors, Sjoerd Rodenhuis.
Breast Cancer Res Treat, 2009 Feb 14; 119(3). PMID: 19214742
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
D A Berry, H B Muss, +8 authors, L Norton.
J Clin Oncol, 2000 Oct 14; 18(20). PMID: 11032587
Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis Slamon, Wolfgang Eiermann, +21 authors, Breast Cancer International Research Group.
N Engl J Med, 2011 Oct 14; 365(14). PMID: 21991949    Free PMC article.
Highly Cited.
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Raimund Jakesz, Walter Jonat, +12 authors, ABCSG and the GABG.
Lancet, 2005 Aug 09; 366(9484). PMID: 16084253
Highly Cited.
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
Aman U Buzdar, Vicente Valero, +13 authors, Gabriel N Hortobagyi.
Clin Cancer Res, 2007 Jan 04; 13(1). PMID: 17200359
Highly Cited.
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
Comprehensive management of locally advanced breast cancer.
G N Hortobagyi.
Cancer, 1990 Sep 15; 66(6 Suppl). PMID: 2205369
Review.
Pathological complete response and accelerated drug approval in early breast cancer.
Tatiana M Prowell, Richard Pazdur.
N Engl J Med, 2012 Jun 01; 366(26). PMID: 22646508
Highly Cited.
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Harry D Bear, Stewart Anderson, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 Apr 12; 24(13). PMID: 16606972
Highly Cited.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Luca Gianni, Tadeusz Pienkowski, +17 authors, Pinuccia Valagussa.
Lancet Oncol, 2011 Dec 14; 13(1). PMID: 22153890
Highly Cited.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
N Lynn Henry, Jon T Giles, Vered Stearns.
Oncology (Williston Park), 2008 Dec 18; 22(12). PMID: 19086600
Review.
Multifactorial approach to predicting resistance to anthracyclines.
Christine Desmedt, Angelo Di Leo, +25 authors, Christos Sotiriou.
J Clin Oncol, 2011 Mar 23; 29(12). PMID: 21422418
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
Valentina Guarneri, Kristine Broglio, +8 authors, Ana M Gonzalez-Angulo.
J Clin Oncol, 2006 Mar 01; 24(7). PMID: 16505422
Highly Cited.
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.
James J Dignam, Vanja Dukic, +3 authors, Norman Wolmark.
Breast Cancer Res Treat, 2008 Oct 03; 116(3). PMID: 18830816    Free PMC article.
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.
C C McDonald, H J Stewart.
BMJ, 1991 Aug 24; 303(6800). PMID: 1912833    Free PMC article.
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.
G von Minckwitz, J-U Blohmer, +10 authors, German Breast Group.
Ann Oncol, 2004 Dec 16; 16(1). PMID: 15598939
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Laurel A Habel, Steven Shak, +12 authors, Charles P Quesenberry.
Breast Cancer Res, 2006 Jun 02; 8(3). PMID: 16737553    Free PMC article.
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.
Ian C Smith, Steven D Heys, +9 authors, Keith N Ogston.
J Clin Oncol, 2002 Mar 16; 20(6). PMID: 11896092
Highly Cited.
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Francesco Boccardo, Alessandra Rubagotti, +17 authors, Piero Sismondi.
J Clin Oncol, 2005 Jul 13; 23(22). PMID: 16009955
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
BIG 1-98 Collaborative Group, Henning Mouridsen, +10 authors, Alan S Coates.
N Engl J Med, 2009 Aug 21; 361(8). PMID: 19692688    Free PMC article.
Highly Cited.
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women.
V Guetta, R M Lush, +2 authors, R O Cannon.
Am J Cardiol, 1995 Nov 15; 76(14). PMID: 7484866
Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.
Michail Ignatiadis, Sandeep K Singhal, +7 authors, Christos Sotiriou.
J Clin Oncol, 2012 Apr 18; 30(16). PMID: 22508827
Highly Cited.
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
E de Azambuja, F Cardoso, +7 authors, M Paesmans.
Br J Cancer, 2007 Apr 25; 96(10). PMID: 17453008    Free PMC article.
Highly Cited.
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
R C Coombes, L S Kilburn, +32 authors, Intergroup Exemestane Study.
Lancet, 2007 Feb 20; 369(9561). PMID: 17307102
Highly Cited.
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
Hervé Bonnefoi, Martine Piccart, +19 authors, EORTC 10994/BIG 1-00 Study Investigators.
Lancet Oncol, 2011 May 17; 12(6). PMID: 21570352    Free PMC article.
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Karine Briot, Michèle Tubiana-Hulin, +2 authors, Christian Roux.
Breast Cancer Res Treat, 2009 Dec 26; 120(1). PMID: 20035381
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B Fisher, J Bryant, +13 authors, H D Bear.
J Clin Oncol, 1998 Aug 15; 16(8). PMID: 9704717
Highly Cited.
Ki67 in breast cancer: prognostic and predictive potential.
Rinat Yerushalmi, Ryan Woods, +2 authors, Karen A Gelmon.
Lancet Oncol, 2010 Feb 16; 11(2). PMID: 20152769
Highly Cited. Review.
Defining the benefits of neoadjuvant chemotherapy for breast cancer.
Anne F Schott, Daniel F Hayes.
J Clin Oncol, 2012 Apr 18; 30(15). PMID: 22508810
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
J A Foekens, H A Peters, +9 authors, J G Klijn.
Cancer Res, 2000 Feb 17; 60(3). PMID: 10676647
Highly Cited.
Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?
Takayuki Iwamoto, Lajos Pusztai.
Genome Med, 2010 Nov 26; 2(11). PMID: 21092148    Free PMC article.
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Luisa Bonilla, Irit Ben-Aharon, +3 authors, Salomon M Stemmer.
J Natl Cancer Inst, 2010 Nov 26; 102(24). PMID: 21098761    Free PMC article.
Systematic Review.
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
Tomasz Byrski, Jacek Gronwald, +10 authors, Steven Narod.
J Clin Oncol, 2009 Dec 17; 28(3). PMID: 20008645
Highly Cited.
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.
N Wolmark, J Wang, +2 authors, B Fisher.
J Natl Cancer Inst Monogr, 2002 Jan 05; (30). PMID: 11773300
Highly Cited.
Management of locally advanced breast cancer.
G N Hortobagyi, A U Buzdar.
Am J Clin Oncol, 1988 Oct 01; 11(5). PMID: 2845771
HER-2 and topoisomerase II as predictors of response to chemotherapy.
Kathleen I Pritchard, Hans Messersmith, +3 authors, Bindi Dhesy-Thind.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258981
Review.
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
Mitch Dowsett, Torsten O Nielsen, +19 authors, International Ki-67 in Breast Cancer Working Group.
J Natl Cancer Inst, 2011 Oct 01; 103(22). PMID: 21960707    Free PMC article.
Highly Cited.
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.
C Mazouni, S-W Kau, +10 authors, L Pusztai.
Ann Oncol, 2007 Feb 13; 18(5). PMID: 17293601
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
G Viale, M M Regan, +17 authors, BIG 1-98 Collaborative and International Breast Cancer Study Groups.
Ann Oncol, 2011 Feb 22; 22(10). PMID: 21335417    Free PMC article.
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
Stephen E Jones, Michael A Savin, +17 authors, Lina Asmar.
J Clin Oncol, 2006 Dec 01; 24(34). PMID: 17135639
Highly Cited.
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
Harold J Burstein, Ann Alexis Prestrud, +16 authors, American Society of Clinical Oncology.
J Clin Oncol, 2010 Jul 14; 28(23). PMID: 20625130    Free PMC article.
Highly Cited. Systematic Review.
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Torsten O Nielsen, Joel S Parker, +12 authors, Matthew J Ellis.
Clin Cancer Res, 2010 Sep 15; 16(21). PMID: 20837693    Free PMC article.
Highly Cited.
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.
M Kaufmann, G von Minckwitz, +16 authors, S Loibl.
Ann Oncol, 2007 Nov 14; 18(12). PMID: 17998286
Review.
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
J A van der Hage, C J van de Velde, +3 authors, L Duchateau.
J Clin Oncol, 2001 Nov 16; 19(22). PMID: 11709566
Highly Cited.
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
M Baum, A Buzdar, +5 authors, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.
Cancer, 2003 Oct 30; 98(9). PMID: 14584060
Highly Cited.
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Aman U Buzdar, Nuhad K Ibrahim, +17 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2005 Mar 02; 23(16). PMID: 15738535
Highly Cited.
Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer.
A E Ring, I E Smith, +2 authors, S R Lakhani.
Br J Cancer, 2004 Nov 24; 91(12). PMID: 15558072    Free PMC article.
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Alessandra Gennari, Maria Pia Sormani, +4 authors, Paolo Bruzzi.
J Natl Cancer Inst, 2007 Dec 27; 100(1). PMID: 18159072
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, +10 authors, Lajos Pusztai.
J Clin Oncol, 2008 Feb 06; 26(8). PMID: 18250347
Highly Cited.
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Michael Gnant, Brigitte Mlineritsch, +20 authors, C Marth.
N Engl J Med, 2009 Feb 14; 360(7). PMID: 19213681
Highly Cited.
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
Michele De Laurentiis, Giuseppe Cancello, +13 authors, Sabino De Placido.
J Clin Oncol, 2008 Jan 01; 26(1). PMID: 18165639
Highly Cited.
Breast cancer classification and prognosis based on gene expression profiles from a population-based study.
Christos Sotiriou, Soek-Ying Neo, +7 authors, Edison T Liu.
Proc Natl Acad Sci U S A, 2003 Aug 15; 100(18). PMID: 12917485    Free PMC article.
Highly Cited.
Indications for neoadjuvant chemotherapy for breast cancer.
H D Bear.
Semin Oncol, 1998 May 05; 25(2 Suppl 3). PMID: 9566201
Review.
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
Takayuki Iwamoto, Giampaolo Bianchini, +14 authors, Lajos Pusztai.
J Natl Cancer Inst, 2010 Dec 31; 103(3). PMID: 21191116
Highly Cited.
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
José Baselga, Javier Cortés, +12 authors, CLEOPATRA Study Group.
N Engl J Med, 2011 Dec 14; 366(2). PMID: 22149875    Free PMC article.
Highly Cited.
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade.
Britta Weigelt, Frederick L Baehner, Jorge S Reis-Filho.
J Pathol, 2009 Nov 21; 220(2). PMID: 19927298
Highly Cited. Review.
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
Giuseppe Viale, Meredith M Regan, +16 authors, International Breast Cancer Study Group.
J Natl Cancer Inst, 2008 Jan 31; 100(3). PMID: 18230798
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Michael Untch, Mahdi Rezai, +17 authors, Gunter von Minckwitz.
J Clin Oncol, 2010 Mar 24; 28(12). PMID: 20308670
Highly Cited.
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Daniel P Silver, Andrea L Richardson, +19 authors, Judy E Garber.
J Clin Oncol, 2010 Jan 27; 28(7). PMID: 20100965    Free PMC article.
Highly Cited.
Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
Cornelia Liedtke, Christos Hatzis, +8 authors, Lajos Pusztai.
J Clin Oncol, 2009 Apr 15; 27(19). PMID: 19364972    Free PMC article.
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Angelo Di Leo, Christine Desmedt, +19 authors, HER2/TOP2A Meta-analysis Study Group.
Lancet Oncol, 2011 Sep 16; 12(12). PMID: 21917518
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
N Harbeck, M Schmitt, +12 authors, Chemo-N 0 Study Group.
Eur J Cancer, 2013 Mar 16; 49(8). PMID: 23490655
Trastuzumab containing regimens for early breast cancer.
Lorenzo Moja, Ludovica Tagliabue, +4 authors, Roberto D'Amico.
Cochrane Database Syst Rev, 2012 Apr 20; (4). PMID: 22513938    Free PMC article.
Highly Cited. Systematic Review.
Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
Dawn L Hershman, Lawrence H Kushi, +7 authors, Alfred I Neugut.
J Clin Oncol, 2010 Jun 30; 28(27). PMID: 20585090    Free PMC article.
Highly Cited.
Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.
Robin L Jones, Janine Salter, +5 authors, Mitchell Dowsett.
Breast Cancer Res Treat, 2009 Feb 28; 119(2). PMID: 19247830
Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.
Katherine D Crew, Heather Greenlee, +5 authors, Dawn L Hershman.
J Clin Oncol, 2007 Sep 01; 25(25). PMID: 17761973
Highly Cited.
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
B Fisher, J Dignam, +10 authors, R G Margolese.
J Natl Cancer Inst, 1997 Dec 09; 89(22). PMID: 9390536
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Breast International Group (BIG) 1-98 Collaborative Group, Beat Thürlimann, +13 authors, Aron Goldhirsch.
N Engl J Med, 2005 Dec 31; 353(26). PMID: 16382061
Highly Cited.
Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer.
Allan Hackshaw, Michael Roughton, +4 authors, Michael Baum.
J Clin Oncol, 2011 Mar 23; 29(13). PMID: 21422412
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Paul E Goss, James N Ingle, +15 authors, Joseph L Pater.
J Natl Cancer Inst, 2005 Sep 08; 97(17). PMID: 16145047
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
Rosalba Torrisi, Alessandra Balduzzi, +9 authors, Marco Colleoni.
Cancer Chemother Pharmacol, 2007 Dec 08; 62(4). PMID: 18064460
Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.
Ann H Partridge, Andrea LaFountain, +3 authors, Aviva Asnis-Alibozek.
J Clin Oncol, 2008 Jan 09; 26(4). PMID: 18180462
Highly Cited.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Christina Davies, Hongchao Pan, +36 authors, Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.
Lancet, 2012 Dec 12; 381(9869). PMID: 23219286    Free PMC article.
Highly Cited.
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
Cornelis J H van de Velde, Daniel Rea, +14 authors, Stephen E Jones.
Lancet, 2011 Jan 21; 377(9762). PMID: 21247627
Highly Cited.
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
Jenny C Chang, Eric C Wooten, +8 authors, Peter O'Connell.
Lancet, 2003 Aug 09; 362(9381). PMID: 12907009
Highly Cited.
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
N Lynn Henry, Faouzi Azzouz, +10 authors, Anna Maria Storniolo.
J Clin Oncol, 2012 Feb 15; 30(9). PMID: 22331951    Free PMC article.
Highly Cited.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
José Baselga, Ian Bradbury, +25 authors, NeoALTTO Study Team.
Lancet, 2012 Jan 20; 379(9816). PMID: 22257673    Free PMC article.
Highly Cited.
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Maxime P Look, Wim L J van Putten, +37 authors, John A Foekens.
J Natl Cancer Inst, 2002 Jan 17; 94(2). PMID: 11792750
Highly Cited.
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
S Aebi, T Davidson, +2 authors, ESMO Guidelines Working Group.
Ann Oncol, 2011 Oct 20; 22 Suppl 6. PMID: 21908498
A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.
Michael S Ewer, Stefan Glück.
Cancer, 2009 Feb 24; 115(9). PMID: 19235248
Review.
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
Marc Spielmann, Henri Roché, +17 authors, Frédérique Penault-Llorca.
J Clin Oncol, 2009 Nov 18; 27(36). PMID: 19917839
Highly Cited.
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, +14 authors, Sibylle Loibl.
J Clin Oncol, 2012 Apr 18; 30(15). PMID: 22508812
Highly Cited.
HER2 and response to paclitaxel in node-positive breast cancer.
Daniel F Hayes, Ann D Thor, +14 authors, Cancer and Leukemia Group B (CALGB) Investigators.
N Engl J Med, 2007 Oct 12; 357(15). PMID: 17928597
Highly Cited.
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, +9 authors, L Norton.
N Engl J Med, 2001 Mar 15; 344(11). PMID: 11248153
Highly Cited.
Gene-expression signatures in breast cancer.
Christos Sotiriou, Lajos Pusztai.
N Engl J Med, 2009 Feb 21; 360(8). PMID: 19228622
Highly Cited. Review.
A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer.
Andrew E Teschendorff, Carlos Caldas.
Breast Cancer Res, 2008 Aug 30; 10(4). PMID: 18755024    Free PMC article.
Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
H Bonnefoi, S Diebold-Berger, +9 authors, M Piccart.
Ann Oncol, 2003 Feb 25; 14(3). PMID: 12598346
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Marc L Citron, Donald A Berry, +18 authors, Larry Norton.
J Clin Oncol, 2003 Apr 02; 21(8). PMID: 12668651
Highly Cited.
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.
M Knauer, F Cardoso, +4 authors, L J van 't Veer.
Br J Cancer, 2010 Nov 18; 103(12). PMID: 21081926    Free PMC article.
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.
Carsten Denkert, Sibylle Loibl, +14 authors, Gunter von Minckwitz.
J Clin Oncol, 2009 Nov 18; 28(1). PMID: 19917869
Highly Cited.
Multimodal treatment of locoregionally advanced breast cancer.
G N Hortobagyi, G R Blumenschein, +4 authors, F Schell.
Cancer, 1983 Mar 01; 51(5). PMID: 6687377
Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Helena R Chang, John Glaspy, +4 authors, Jeffrey Gornbein.
Cancer, 2010 Jun 16; 116(18). PMID: 20549829
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Paul E Goss, James N Ingle, +18 authors, Lois E Shepherd.
J Clin Oncol, 2013 Jan 30; 31(11). PMID: 23358971    Free PMC article.
Highly Cited.
Molecular profiling: moving away from tumor philately.
Jorge S Reis-Filho, Britta Weigelt, Debora Fumagalli, Christos Sotiriou.
Sci Transl Med, 2010 Sep 03; 2(47). PMID: 20811040
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).
Hannah M Linden, Charles M Haskell, +8 authors, Silvana Martino.
J Clin Oncol, 2007 Feb 20; 25(6). PMID: 17308269
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
Christos Sotiriou, Pratyaksha Wirapati, +17 authors, Mauro Delorenzi.
J Natl Cancer Inst, 2006 Feb 16; 98(4). PMID: 16478745
Highly Cited.
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Sherene Loi, Nicolas Sirtaine, +13 authors, Christos Sotiriou.
J Clin Oncol, 2013 Jan 24; 31(7). PMID: 23341518
Highly Cited.
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
LHRH-agonists in Early Breast Cancer Overview group, J Cuzick, +5 authors, R Sainsbury.
Lancet, 2007 May 22; 369(9574). PMID: 17512856
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Priya Rastogi, Stewart J Anderson, +15 authors, Norman Wolmark.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258986
Highly Cited.
Proliferation marker Ki-67 in early breast cancer.
Ander Urruticoechea, Ian E Smith, Mitch Dowsett.
J Clin Oncol, 2005 Sep 30; 23(28). PMID: 16192605
Highly Cited. Review.
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.
Stephen K Chia, Vivien H Bramwell, +12 authors, Torsten O Nielsen.
Clin Cancer Res, 2012 Jun 20; 18(16). PMID: 22711706    Free PMC article.
Highly Cited.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
Kimberly L Blackwell, Harold J Burstein, +9 authors, Joyce O'Shaughnessy.
J Clin Oncol, 2010 Feb 04; 28(7). PMID: 20124187
Highly Cited.
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Prudence Francis, John Crown, +17 authors, BIG 02-98 Collaborative Group.
J Natl Cancer Inst, 2008 Jan 10; 100(2). PMID: 18182617
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.
Christine Desmedt, Benjamin Haibe-Kains, +6 authors, Christos Sotiriou.
Clin Cancer Res, 2008 Aug 14; 14(16). PMID: 18698033
Highly Cited.
Clinical application of the 70-gene profile: the MINDACT trial.
Fatima Cardoso, Laura Van't Veer, +3 authors, Martine J Piccart-Gebhart.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258980
Highly Cited.
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
Gunter von Minckwitz, Mahdi Rezai, +17 authors, Michael Untch.
J Clin Oncol, 2010 Mar 24; 28(12). PMID: 20308671
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Heikki Joensuu, Petri Bono, +17 authors, Pirkko-Liisa Kellokumpu-Lehtinen.
J Clin Oncol, 2009 Nov 04; 27(34). PMID: 19884557
Highly Cited.
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
M Colozza, E Azambuja, +3 authors, M J Piccart.
Ann Oncol, 2005 Jun 28; 16(11). PMID: 15980158
Review.
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
Ann H Partridge, Philip S Wang, Eric P Winer, Jerry Avorn.
J Clin Oncol, 2003 Feb 15; 21(4). PMID: 12586795
Highly Cited.
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.
Roman Rouzier, Lajos Pusztai, +13 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2005 Nov 19; 23(33). PMID: 16293864
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.
B Fisher, J Dignam, J Bryant, N Wolmark.
J Natl Cancer Inst, 2001 May 03; 93(9). PMID: 11333290
A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer.
Fabien Reyal, Martin H van Vliet, +10 authors, Lodewyk F A Wessels.
Breast Cancer Res, 2008 Nov 19; 10(6). PMID: 19014521    Free PMC article.
American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer.
Jennifer J Griggs, Mark R Somerfield, +6 authors, Nancy E Davidson.
J Clin Oncol, 2011 Sep 09; 29(29). PMID: 21900112
Review.
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
R Charles Coombes, Emma Hall, +24 authors, Intergroup Exemestane Study.
N Engl J Med, 2004 Mar 12; 350(11). PMID: 15014181
Highly Cited.
Breast cancer under age 40: a different approach.
D Ribnikar, J M Ribeiro, +6 authors, F Cardoso.
Curr Treat Options Oncol, 2015 Mar 23; 16(4). PMID: 25796377
Review.
Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
Uanderson Resende, César Cabello, Susana Oliveira Botelho Ramalho, Luiz Carlos Zeferino.
BMC Cancer, 2019 Jun 19; 19(1). PMID: 31208353    Free PMC article.